# Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

> **NCT00834210** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 171 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Dapsone
- **DRUG:** Tazarotene

## Key facts

- **NCT ID:** NCT00834210
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2011-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834210, "Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00834210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*